Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel, Double-Blind, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Two Concentrations of Topical TMB-001 for the Treatment of Congenital Ichthyosis

Next Previous
Trial Profile

A Randomized, Parallel, Double-Blind, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Two Concentrations of Topical TMB-001 for the Treatment of Congenital Ichthyosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isotretinoin (Primary)
  • Indications Congenital ichthyosiform erythroderma; X linked Ichthyosis
  • Focus Therapeutic Use
  • Acronyms CONTROL
  • Sponsors Timber Pharmaceuticals; Trex Wind-down

Most Recent Events

  • 15 Feb 2024 According to Timber Pharmaceuticals media release,Timber Pharmaceuticals has changed its name to Trex Wind-down
  • 21 Aug 2023 According to a LEO Pharma media release, TMB-001 has received an breakthrough designation by the FDA, and is on track with an action date as early as mid-2025.
  • 07 Jul 2023 Results of an analysis assessing characteristics of participants who responded to treatment with TMB-001 published in the Clinical and Experimental Dermatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top